在血友病A的基因治疗:成就,挑战和前景
Natasha S Bala1,2, Courtney D Thornburg1,2
1Rady Children's Hospital San Diego, Hemophilia and Thrombosis Treatment Center, San Diego, California.
Seminars in thrombosis and hemostasis
|April 8, 2024
概括
血友病A的基因治疗显示出改善出血率的希望,但面临着诸如可变反应和肝毒性等挑战. 为了长期的有效性和患者护理,需要制定未来的策略.
科学领域:
- 血液学 血液学 血液学
- 基因治疗 基因治疗
- 药理学 药理学是指药理学的学科.
背景情况:
- 血友病A (HA) 护理的进展包括长效疗法和基因疗法.
- 腺相关病毒 (AAV) 载体介导的基因转移旨在在HA患者中产生内源性第八因子 (FVIII).
研究的目的:
- 审查HA基因治疗试验的成功和发展.
- 突出挑战,不良结果和响应的变化.
- 讨论基因治疗方法和未来策略的观点.
主要方法:
- 对HA中AAV载体介导基因转移的临床前和临床试验的审查.
- 对已批准的基因疗法产品瓦洛克托科根 (valoctocogene roxaparvovec) 的分析.
- 检查挑战,包括肝毒性,中和抗体和反应变异性.
主要成果:
- Valoctocogene roxaparvovec显示出改善的出血率和减少了因子替代疗法的使用.
- 响应持续时间和FVIII表达表现出随时间的变化.
- 副作用包括肝毒性,需要免疫抑制和抗AAV抗体.
结论:
- 对HA的基因疗法有潜力,但需要仔细选择患者和长期监测.
- 应对响应变化和不良影响等挑战对于现实应用至关重要.
- 未来的战略和共享决策对于克服HA基因疗法的未满足需求至关重要.
相关概念视频
00:59Gene Therapy
25.4K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
25.4K
01:59CRISPR
50.8K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
50.8K
00:49What is Genetic Engineering?
74.1K
Overview
74.1K